Clinical trial
Motexafin Gadolinium in Treating Patients With Glioblastoma Multiforme Who Are…
NCT00032097 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00032097 |
|---|---|
| Title | Motexafin Gadolinium in Treating Patients With Glioblastoma Multiforme Who Are Undergoing Radiation Therapy to the Brain |
| Official title | A Phase I Trial To Evaluate Repetitive Intravenous Doses Of Gadolinium-Texaphyrin As A Radiosensitizer In Patients With Glioblastoma Multi Forme |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug, Radiation |
| Interventions | motexafin gadolinium, radiation therapy |
| Start date | Apr 1, 2002 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 9, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: